Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is inviting applications for the Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional). This funding opportunity aims to support investigator-initiated clinical trials that advance regenerative medicine, particularly using adult stem cells, as outlined by the 21st Century Cures Act. The initiative is crucial for enhancing research on regenerative therapies and addressing barriers in clinical development, with a total funding amount of up to $3.5 million available, and a maximum of $400,000 in direct costs per year for each awarded project. Interested applicants must submit their proposals by October 21, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the opportunity's webpage for more details.
Eligible Applicants
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.